The protective functions of omentin in cardiovascular diseases

Clinica Chimica Acta

Volumn 448, Issue , 2015, Pages 98-106

  Tan, Yu Lin ^a,b   Zheng, Xi Long ^c   Tang, Chao Ke ^a  

^a UNIVERSITY OF SOUTH CHINA   (China)

^b XIANGNAN UNIVERSITY   (China)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

Cardiovascular diseases; Omentin; Protective functions

Indexed keywords

ADIPOCYTOKINE; OMENTIN; UNCLASSIFIED DRUG; CYTOKINE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; ITLN1 PROTEIN, HUMAN; LECTIN;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; ENDOTHELIUM; HEART FAILURE; HEART PROTECTION; HUMAN; INFLAMMATION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; NEOPLASM; NONHUMAN; OBESITY; OVARY POLYCYSTIC DISEASE; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; RISK REDUCTION; SLEEP DISORDERED BREATHING; STRUCTURE ANALYSIS; VASODILATATION; ADIPOCYTE; ANIMAL; CARDIOVASCULAR DISEASES; CHEMISTRY; METABOLISM;

ADIPOCYTES; ANIMALS; CARDIOVASCULAR DISEASES; CYTOKINES; GPI-LINKED PROTEINS; HUMANS; INFLAMMATION; INSULIN RESISTANCE; LECTINS; OBESITY;

EID: 84934757615     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2015.05.019     Document Type: Review

References (122)

1. Koleva D.I., Orbetzova M.M., Atanassova P.K. Adipose tissue hormones and appetite and body weight regulators in insulin resistance [J]. Folia Med (Plovdiv) 2013, 55(1):25-32.
2. Jaikanth C., Gurumurthy P., Cherian K.M., et al. Emergence of omentin as a pleiotropic adipocytokine [J]. Exp Clin Endocrinol Diabetes 2013, 121(7):377-383.
3. Zhou J.Y., Chan L., Zhou S.W. Omentin: linking metabolic syndrome and cardiovascular disease [J]. Curr Vasc Pharmacol 2014, 12(1):136-143.
4. Nakamura K., Fuster J.J., Walsh K. Adipokines: a link between obesity and cardiovascular disease [J]. J Cardiol 2014, 63(4):250-259.
5. Katsi V., Vamvakou G., Lekakis J., et al. Omentin, fat and heart: classical music with new instruments [J]. Heart Lung Circ 2014, 23(9):802-806.
6. Schaffler A., Neumeier M., Herfarth H., et al. Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue [J]. Biochim Biophys Acta 2005, 1732(1-3):96-102.
7. Yang R.Z., Lee M.J., Hu H., et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action [J]. Am J Physiol Endocrinol Metab 2006, 290(6):E1253-E1261.
8. Suzuki Y.A., Shin K., Lonnerdal B. Molecular cloning and functional expression of a human intestinal lactoferrin receptor [J]. Biochemistry 2001, 40(51):15771-15779.
9. Komiya T., Tanigawa Y., Hirohashi S. Cloning of the novel gene intelectin, which is expressed in intestinal paneth cells in mice [J]. Biochem Biophys Res Commun 1998, 251(3):759-762.
10. Lee J.K., Schnee J., Pang M., et al. Human homologs of the Xenopus oocyte cortical granule lectin XL35 [J]. Glycobiology 2001, 11(1):65-73.
11. Tan B.K., Adya R., Randeva H.S. Omentin: a novel link between inflammation, diabesity, and cardiovascular disease [J]. Trends Cardiovasc Med 2010, 20(5):143-148.
12. Gerwick L., Corley-Smith G., Bayne C.J. Gene transcript changes in individual rainbow trout livers following an inflammatory stimulus [J]. Fish Shellfish Immunol 2007, 22(3):157-171.
13. Havel P.J. Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism [J]. Diabetes 2004, 53(Suppl. 1):S143-S151.
14. Sengul E., Duygulu G., Dindar S., et al. Serum omentin-1, inflammation and carotid atherosclerosis in patients with non-diabetic chronic kidney disease [J]. Ren Fail 2013, 35(8):1089-1093.
15. Yamawaki H., Kuramoto J., Kameshima S., et al. Omentin, a novel adipocytokine inhibits TNF-induced vascular inflammation in human endothelial cells [J]. Biochem Biophys Res Commun 2011, 408(2):339-343.
16. Xu L., Zhu G.B., Wang L., et al. Synovial fluid omentin-1 levels are inversely correlated with radiographic severity of knee osteoarthritis [J]. J Invest Med 2012, 60(3):583-586.
17. Kuperman D.A., Lewis C.C., Woodruff P.G., et al. Dissecting asthma using focused transgenic modeling and functional genomics [J]. J Allergy Clin Immunol 2005, 116(2):305-311.
18. Wang C. Obesity, inflammation, and lung injury (OILI): the good [J]. Mediators Inflamm 2014, 2014:978463.
19. Xue Y., Jiang L., Cheng Q., et al. Adipokines in psoriatic arthritis patients: the correlations with osteoclast precursors and bone erosions [J]. PLoS One 2012, 7(10):e46740.
20. Turkcu F.M., Sahin A., Cingu A.K., et al. Serum omentin, resistin and tumour necrosis factor-alpha levels in Behcet patients with and without ocular involvement [J]. Graefes Arch Clin Exp Ophthalmol 2015 Apr 23, [Epub ahead of print].
21. Sit M., Aktas G., Yilmaz E.E., et al. Effects of the inflammatory response on serum omentin levels in early acute and chronic pancreatitis [J]. Clin Ter 2014, 165(2):e148-e152.
22. Lu Y., Zhou L., Liu L., et al. Serum omentin-1 as a disease activity marker for Crohn's disease [J]. Dis Markers 2014, 2014:162517.
23. Yin J., Hou P., Wu Z., et al. Decreased levels of serum omentin-1 in patients with inflammatory bowel disease [J]. Med Sci Monit 2015, 21:118-122.
24. Schaffler A., Zeitoun M., Wobser H., et al. Frequency and significance of the novel single nucleotide missense polymorphism Val109Asp in the human gene encoding omentin in Caucasian patients with type 2 diabetes mellitus or chronic inflammatory bowel diseases [J]. Cardiovasc Diabetol 2007, 6:3.
25. Sit M., Aktas G., Yilmaz E.E., et al. Serum omentin levels predicts mesenteric ischemia [J]. Bratisl Lek Listy 2015, 116(3):173-176.
26. Yilmaz Y., Yonal O., Kurt R., et al. Serum levels of omentin, chemerin and adipsin in patients with biopsy-proven nonalcoholic fatty liver disease [J]. Scand J Gastroenterol 2011, 46(1):91-97.
27. Alcelik A., Tosun M., Ozlu M.F., et al. Serum levels of omentin in end-stage renal disease patients [J]. Kidney Blood Press Res 2012, 35(6):511-516.
28. Barker G., Lim R., Georgiou H.M., et al. Omentin-1 is decreased in maternal plasma, placenta and adipose tissue of women with pre-existing obesity [J]. PLoS One 2012, 7(8):e42943.
29. Maruyama S., Shibata R., Kikuchi R., et al. Fat-derived factor omentin stimulates endothelial cell function and ischemia-induced revascularization via endothelial nitric oxide synthase-dependent mechanism [J]. J Biol Chem 2012, 287(1):408-417.
30. Brunetti L., Leone S., Orlando G., et al. Hypotensive effects of omentin-1 related to increased adiponectin and decreased interleukin-6 in intra-thoracic pericardial adipose tissue [J]. Pharmacol Rep 2014, 66(6):991-995.
31. Ohashi K., Shibata R., Murohara T., et al. Role of anti-inflammatory adipokines in obesity-related diseases [J]. Trends Endocrinol Metab 2014, 25(7):348-355.
32. Bergmann K., Sypniewska G. Diabetes as a complication of adipose tissue dysfunction. Is there a role for potential new biomarkers? [J]. Clin Chem Lab Med 2013, 51(1):177-185.
33. Lo K.A., Sun L. Turning WAT into BAT: a review on regulators controlling the browning of white adipocytes [J]. Biosci Rep 2013, 33(5).
34. Yamawaki H. Vascular effects of novel adipocytokines: focus on vascular contractility and inflammatory responses [J]. Biol Pharm Bull 2011, 34(3):307-310.
35. Poirier P., Giles T.D., Bray G.A., et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss [J]. Arterioscler Thromb Vasc Biol 2006, 26(5):968-976.
36. Olarescu N.C., Heck A., Godang K., et al. The metabolic risk in newly diagnosed patients with acromegaly is related to fat distribution and circulating adipokines and improves after treatment [J]. Neuroendocrinology 2015.
37. Bonet M.L., Oliver P., Palou A. Pharmacological and nutritional agents promoting browning of white adipose tissue [J]. Biochim Biophys Acta 2013, 1831(5):969-985.
38. Shibata R., Ouchi N., Kikuchi R., et al. Circulating omentin is associated with coronary artery disease in men [J]. Atherosclerosis 2011, 219(2):811-814.
39. Barth S., Klein P., Horbach T., et al. Expression of neuropeptide Y, omentin and visfatin in visceral and subcutaneous adipose tissues in humans: relation to endocrine and clinical parameters [J]. Obes Facts 2010, 3(4):245-251.
40. Auguet T., Quintero Y., Riesco D., et al. New adipokines vaspin and omentin. Circulating levels and gene expression in adipose tissue from morbidly obese women [J]. BMC Med Genet 2011, 12:60.
41. Yan P., Liu D., Long M., et al. Changes of serum omentin levels and relationship between omentin and adiponectin concentrations in type 2 diabetes mellitus [J]. Exp Clin Endocrinol Diabetes 2011, 119(4):257-263.
42. de Souza Batista C.M., Yang R.Z., Lee M.J., et al. Omentin plasma levels and gene expression are decreased in obesity [J]. Diabetes 2007, 56(6):1655-1661.
43. Brunetti L., Di Nisio C., Recinella L., et al. Effects of vaspin, chemerin and omentin-1 on feeding behavior and hypothalamic peptide gene expression in the rat [J]. Peptides 2011, 32(9):1866-1871.
44. Bremer A.A., Jialal I. Adipose tissue dysfunction in nascent metabolic syndrome [J]. J Obes 2013, 2013:393192.
45. Cai R.C., Wei L., Di J.Z., et al. [Expression of omentin in adipose tissues in obese and type 2 diabetic patients] [J]. Zhonghua Yi Xue Za Zhi 2009, 89(6):381-384.
46. Pan H.Y., Guo L., Li Q. Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes [J]. Diabetes Res Clin Pract 2010, 88(1):29-33.
47. Sitticharoon C., Nway N.C., Chatree S., et al. Interactions between adiponectin, visfatin, and omentin in subcutaneous and visceral adipose tissues and serum, and correlations with clinical and peripheral metabolic factors [J]. Peptides 2014, 62:164-175.
48. Zhang Q., Zhu L., Zheng M., et al. Changes of serum omentin-1 levels in normal subjects, type 2 diabetes and type 2 diabetes with overweight and obesity in Chinese adults [J]. Ann Endocrinol (Paris) 2014, 75(3):171-175.
49. Urbanova M., Dostalova I., Trachta P., et al. Serum concentrations and subcutaneous adipose tissue mRNA expression of omentin in morbid obesity and type 2 diabetes mellitus: the effect of very-low-calorie diet, physical activity and laparoscopic sleeve gastrectomy [J]. Physiol Res 2014, 63(2):207-218.
50. Redondo M.J., Rodriguez L.M., Haymond M.W., et al. Serum adiposity-induced biomarkers in obese and lean children with recently diagnosed autoimmune type 1 diabetes [J]. Pediatr Diabetes 2014, 15(8):543-549.
51. Moreno-Navarrete J.M., Catalan V., Ortega F., et al. Circulating omentin concentration increases after weight loss [J]. Nutr Metab (Lond) 2010, 7:27.
52. Siejka A., Jankiewicz-Wika J., Kolomecki K., et al. Long-term impact of vertical banded gastroplasty (VBG) on plasma concentration of leptin, soluble leptin receptor, ghrelin, omentin-1, obestatin, and retinol binding protein 4 (RBP4) in patients with severe obesity [J]. Cytokine 2013, 64(2):490-493.
53. Oswiecimska J., Suwala A., Swietochowska E., et al. Serum omentin levels in adolescent girls with anorexia nervosa and obesity [J]. Physiol Res 2015.
54. Wilms B., Ernst B., Gerig R., et al. Plasma omentin-1 levels are related to exercise performance in obese women and increase upon aerobic endurance training [J]. Exp Clin Endocrinol Diabetes 2015, 123(3):187-192.
55. Peraire J., Lopez-Dupla M., Alba V., et al. HIV/antiretroviral therapy-related lipodystrophy syndrome (HALS) is associated with higher RBP4 and lower omentin in plasma [J]. Clin Microbiol Infect 2015, 21(7):711.e1-711.e8.
56. Splichal Z., Bienertova-Vasku J., Novak J., et al. The common polymorphism Val109Asp in the omentin gene is associated with daily energy intake in the Central-European population [J]. Nutr Neurosci 2015, 18(1):41-48.
57. Tan B.K., Adya R., Farhatullah S., et al. Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome: ex vivo and in vivo regulation of omentin-1 by insulin and glucose [J]. Diabetes 2008, 57(4):801-808.
58. Orlik B., Madej P., Owczarek A., et al. Plasma omentin and adiponectin levels as markers of adipose tissue dysfunction in normal weight and obese women with polycystic ovary syndrome [J]. Clin Endocrinol (Oxf) 2014, 81(4):529-535.
59. Guzel E.C., Celik C., Abali R., et al. Omentin and chemerin and their association with obesity in women with polycystic ovary syndrome [J]. Gynecol Endocrinol 2014, 30(6):419-422.
60. Choi J.H., Rhee E.J., Kim K.H., et al. Plasma omentin-1 levels are reduced in non-obese women with normal glucose tolerance and polycystic ovary syndrome [J]. Eur J Endocrinol 2011, 165(5):789-796.
61. Shaker M., Mashhadani Z.I., Mehdi A.A. Effect of treatment with metformin on omentin-1, ghrelin and other biochemical, clinical features in PCOS patients [J]. Oman Med J 2010, 25(4):289-293.
62. Olszanecka-Glinianowicz M., Madej P., Owczarek A., et al. Circulating anti-Mullerian hormone levels in relation to nutritional status and selected adipokines levels in polycystic ovary syndrome [J]. Clin Endocrinol (Oxf) 2014, 83(1):98-104.
63. Carmina E. Obesity, adipokines and metabolic syndrome in polycystic ovary syndrome [J]. Front Horm Res 2013, 40:40-50.
64. Zirlik S., Hildner K.M., Targosz A., et al. Melatonin and omentin: influence factors in the obstructive sleep apnoea syndrome? [J]. J Physiol Pharmacol 2013, 64(3):353-360.
65. Wang Q., Feng X., Zhou C., et al. Decreased levels of serum omentin-1 in patients with obstructive sleep apnoea syndrome [J]. Ann Clin Biochem 2013, 50(Pt 3):230-235.
66. Kurt O.K., Tosun M., Alcelik A., et al. Serum omentin levels in patients with obstructive sleep apnea [J]. Sleep Breath 2014, 18(2):391-395.
67. Calvin A.D., Albuquerque F.N., Lopez-Jimenez F., et al. Obstructive sleep apnea, inflammation, and the metabolic syndrome [J]. Metab Syndr Relat Disord 2009, 7(4):271-278.
68. Lewandowski K., Nadel I., Lewinski A., et al. Positive correlation between serum omentin and thrombospondin-1 in gestational diabetes despite lack of correlation with insulin resistance indices [J]. Ginekol Pol 2010, 81(12):907-912.
69. Fasshauer M., Bluher M., Stumvoll M. Adipokines in gestational diabetes [J]. Lancet Diabetes Endocrinol 2014, 2(6):488-499.
70. Aktas G., Alcelik A., Ozlu T., et al. Association between omentin levels and insulin resistance in pregnancy [J]. Exp Clin Endocrinol Diabetes 2014, 122(3):163-166.
71. Brandt B., Mazaki-Tovi S., Hemi R., et al. Omentin, an adipokine with insulin-sensitizing properties, is negatively associated with insulin resistance in normal gestation [J]. J Perinat Med 2014, 43(3):325-331.
72. Tekce H., Tekce B.K., Aktas G., et al. Serum omentin-1 levels in diabetic and nondiabetic patients with chronic kidney disease [J]. Exp Clin Endocrinol Diabetes 2014, 122(8):451-456.
73. Zhang Y.Y., Zhou L.M. Omentin-1, a new adipokine, promotes apoptosis through regulating Sirt1-dependent p53 deacetylation in hepatocellular carcinoma cells [J]. Eur J Pharmacol 2013, 698(1-3):137-144.
74. Uyeturk U., Sarici H., Kin Tekce B., et al. Serum omentin level in patients with prostate cancer [J]. Med Oncol 2014, 31(4):923.
75. Uyeturk U., Alcelik A., Aktas G., et al. Post-treatment plasma omentin levels in patients with stage III colon carcinoma [J]. J BUON 2014, 19(3):681-685.
76. Fazeli M.S., Dashti H., Akbarzadeh S., et al. Circulating levels of novel adipocytokines in patients with colorectal cancer [J]. Cytokine 2013, 62(1):81-85.
77. Wada J. Vaspin: a novel serpin with insulin-sensitizing effects [J]. Expert Opin Investig Drugs 2008, 17(3):327-333.
78. Booth A., Magnuson A., Fouts J., et al. Adipose tissue, obesity and adipokines: role in cancer promotion [J]. Horm Mol Biol Clin Investig 2015, 21(1):57-74.
79. Zheng L., Weng M., Qi M., et al. Aberrant expression of intelectin-1 in gastric cancer: its relationship with clinicopathological features and prognosis [J]. J Cancer Res Clin Oncol 2012, 138(1):163-172.
80. Yamawaki H., Tsubaki N., Mukohda M., et al. Omentin, a novel adipokine, induces vasodilation in rat isolated blood vessels [J]. Biochem Biophys Res Commun 2010, 393(4):668-672.
81. Zhong X., Li X., Liu F., et al. Omentin inhibits TNF-alpha-induced expression of adhesion molecules in endothelial cells via ERK/NF-kappaB pathway [J]. Biochem Biophys Res Commun 2012, 425(2):401-406.
82. Wang Z., Nakayama T. Inflammation, a link between obesity and cardiovascular disease [J]. Mediators Inflamm 2010, 2010:535918.
83. Moreno-Navarrete J.M., Ortega F., Castro A., et al. Circulating omentin as a novel biomarker of endothelial dysfunction [J]. Obesity (Silver Spring) 2011, 19(8):1552-1559.
84. Kazama K., Okada M., Yamawaki H. A novel adipocytokine, omentin, inhibits monocrotaline-induced pulmonary arterial hypertension in rats [J]. Biochem Biophys Res Commun 2014, 452(1):142-146.
85. Uemura Y., Shibata R., Kanemura N., et al. Adipose-derived protein omentin prevents neointimal formation after arterial injury [J]. FASEB J 2015, 29(1):141-151.
86. Ouwens D.M., Sell H., Greulich S., et al. The role of epicardial and perivascular adipose tissue in the pathophysiology of cardiovascular disease [J]. J Cell Mol Med 2010, 14(9):2223-2234.
87. Montagnani M., Ravichandran L.V., Chen H., et al. Insulin receptor substrate-1 and phosphoinositide-dependent kinase-1 are required for insulin-stimulated production of nitric oxide in endothelial cells [J]. Mol Endocrinol 2002, 16(8):1931-1942.
88. Kazama K., Okada M., Hara Y., et al. A novel adipocytokine, omentin, inhibits agonists-induced increases of blood pressure in rats [J]. J Vet Med Sci 2013, 75(8):1029-1034.
89. Eisinger K., Krautbauer S., Wiest R., et al. Portal vein omentin is increased in patients with liver cirrhosis but is not associated with complications of portal hypertension [J]. Eur J Clin Invest 2013, 43(9):926-932.
90. Tan B.K., Adya R., Farhatullah S., et al. Metformin treatment may increase omentin-1 levels in women with polycystic ovary syndrome [J]. Diabetes 2010, 59(12):3023-3031.
91. Krupinski J., Font A., Luque A., et al. Angiogenesis and inflammation in carotid atherosclerosis [J]. Front Biosci 2008, 13:6472-6482.
92. Van de Voorde J., Pauwels B., Boydens C., et al. Adipocytokines in relation to cardiovascular disease [J]. Metabolism 2013, 62(11):1513-1521.
93. Liu R., Wang X., Bu P. Omentin-1 is associated with carotid atherosclerosis in patients with metabolic syndrome [J]. Diabetes Res Clin Pract 2011, 93(1):21-25.
94. Bley T.A., Johnson K.M., Francois C.J., et al. Noninvasive assessment of transstenotic pressure gradients in porcine renal artery stenoses by using vastly undersampled phase-contrast MR angiography [J]. Radiology 2011, 261(1):266-273.
95. Shibata R., Takahashi R., Kataoka Y., et al. Association of a fat-derived plasma protein omentin with carotid artery intima-media thickness in apparently healthy men [J]. Hypertens Res 2011, 34(12):1309-1312.
96. Jialal I., Devaraj S., Kaur H., et al. Increased chemerin and decreased omentin-1 in both adipose tissue and plasma in nascent metabolic syndrome [J]. J Clin Endocrinol Metab 2013, 98(3):E514-E517.
97. Yoo H.J., Hwang S.Y., Hong H.C., et al. Association of circulating omentin-1 level with arterial stiffness and carotid plaque in type 2 diabetes [J]. Cardiovasc Diabetol 2011, 10:103.
98. Cerit E.T., Akturk M., Altinova A.E., et al. Evaluation of body composition changes, epicardial adipose tissue, and serum omentin-1 levels in overt hypothyroidism [J]. Endocrine 2014, 49(1):196-203.
99. Gao C., Yang B., Guo Q., et al. High thyroid-stimulating hormone level is associated with the risk of developing atherosclerosis in subclinical hypothyroidism [J]. Horm Metab Res 2014, 47(3):220-224.
100. Yoo H.J., Hwang S.Y., Hong H.C., et al. Implication of circulating omentin-1 level on the arterial stiffening in type 2 diabetes mellitus [J]. Endocrine 2013, 44(3):680-687.
101. Oh H.G., Chung P.W., Rhee E.J. Increased risk for intracranial arterial stenosis in subjects with coronary artery calcification [J]. Stroke 2015, 46(1):151-156.
102. Deng L., Huang L., Sun Y., et al. Inhibition of FOXO1/3 promotes vascular calcification [J]. Arterioscler Thromb Vasc Biol 2015, 35(1):175-183.
103. Xie H., Xie P.L., Wu X.P., et al. Omentin-1 attenuates arterial calcification and bone loss in osteoprotegerin-deficient mice by inhibition of RANKL expression [J]. Cardiovasc Res 2011, 92(2):296-306.
104. Duan X.Y., Xie P.L., Ma Y.L., et al. Omentin inhibits osteoblastic differentiation of calcifying vascular smooth muscle cells through the PI3K/Akt pathway [J]. Amino Acids 2011, 41(5):1223-1231.
105. Zhong X., Zhang H.Y., Tan H., et al. Association of serum omentin-1 levels with coronary artery disease [J]. Acta Pharmacol Sin 2011, 32(7):873-878.
106. Panagiotou G., Mu L., Na B., et al. Circulating irisin, omentin-1, and lipoprotein subparticles in adults at higher cardiovascular risk [J]. Metabolism 2014, 63(10):1265-1271.
107. Shang F.J., Wang J.P., Liu X.T., et al. Serum omentin-1 levels are inversely associated with the presence and severity of coronary artery disease in patients with metabolic syndrome [J]. Biomarkers 2011, 16(8):657-662.
108. Onur I., Oz F., Yildiz S., et al. Serum omentin 1 level is associated with coronary artery disease and its severity in postmenopausal women [J]. Angiology 2014, 65(10):896-900.
109. Kadoglou N.P., Tahmatzidis D.K., Giannakoulas C., et al. Serum levels of novel adipokines, omentin-1 and chemerin, in patients with acute myocardial infarction: KOZANI STUDY [J]. J Cardiovasc Med (Hagerstown) 2014, 16(5):341-346.
110. Ucgun T., Basar C., Memisogullari R., et al. Serum visfatin and omentin levels in slow coronary flow [J]. Rev Port Cardiol 2014, 33(12):789-794.
111. Yoruk U., Yaykasli K.O., Ozhan H., et al. Association of omentin Val109Asp polymorphism with coronary artery disease [J]. Anadolu Kardiyol Derg 2014, 14(6):511-514.
112. Wang X.H., Dou L.Z., Gu C., et al. Plasma levels of omentin-1 and visfatin in senile patients with coronary heart disease and heart failure [J]. Asian Pac J Trop Med 2014, 7(1):55-62.
113. Narumi T., Watanabe T., Kadowaki S., et al. Impact of serum omentin-1 levels on cardiac prognosis in patients with heart failure [J]. Cardiovasc Diabetol 2014, 13:84.
114. Ashley E.A., Powers J., Chen M., et al. The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo [J]. Cardiovasc Res 2005, 65(1):73-82.
115. Nadruz W. Myocardial remodeling in hypertension [J]. J Hum Hypertens 2015, 29(1):1-6.
116. Matsuo K., Shibata R., Ohashi K., et al. Omentin functions to attenuate cardiac hypertrophic response [J]. J Mol Cell Cardiol 2015, 79:195-202.
117. Kazama K., Okada M., Yamawaki H. Adipocytokine, omentin inhibits doxorubicin-induced H9c2 cardiomyoblasts apoptosis through the inhibition of mitochondrial reactive oxygen species [J]. Biochem Biophys Res Commun 2015, 457(4):602-607.
118. El-Mesallamy H.O., El-Derany M.O., Hamdy N.M. Serum omentin-1 and chemerin levels are interrelated in patients with Type 2 diabetes mellitus with or without ischaemic heart disease [J]. Diabet Med 2011, 28(10):1194-1200.
119. Kataoka Y., Shibata R., Ohashi K., et al. Omentin prevents myocardial ischemic injury through AMP-activated protein kinase- and Akt-dependent mechanisms [J]. J Am Coll Cardiol 2014, 63(24):2722-2733.
120. Miura S., Asano Y., Saigusa R., et al. Serum omentin levels: a possible contribution to vascular involvement in patients with systemic sclerosis [J]. J Dermatol 2015, 42(5):461-466.
121. Kadoglou N.P., Lambadiari V., Gastounioti A., et al. The relationship of novel adipokines, RBP4 and omentin-1, with carotid atherosclerosis severity and vulnerability [J]. Atherosclerosis 2014, 235(2):606-612.
122. Flehmig G., Scholz M., Kloting N., et al. Identification of adipokine clusters related to parameters of fat mass, insulin sensitivity and inflammation [J]. PLoS One 2014, 9(6):e99785.